ONESOURCE SPECL PHARMA L Latest Share Price (ONESOURCE)
TODAY IN ONE LINE
ONESOURCE jumped 3.3% on above-average volume (4.9x avg), outperforming Nifty's -0.3% move, with no exchange filing today, suggesting a market-driven move.
With a market cap of ₹18,225.24 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
ONESOURCE SPECL PHARMA L flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.21x
- ●FII AccumulationFII holding increased by 1.69% QoQ
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 95.3% YoY
- ●Sales ContractionQuarterly sales dropped 0.6% YoY
- ●Poor Capital ReturnsLow ROE of 0.4%
- ●Promoter SellingPromoter holding decreased by 30.48% QoQ
Latest ONESOURCE SPECL PHARMA L News
What changed recently?
Recent events, corporate actions, and announcements.
ONESOURCE SPECL PHARMA L valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for ONESOURCE SPECL PHARMA L, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
ONESOURCE SPECL PHARMA L technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for ONESOURCE SPECL PHARMA L — derived from the latest tape, not yesterday's close.
ONESOURCE SPECL PHARMA L last traded at ₹1,592.2 with an intraday range of ₹1,530–₹1,624.7 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1592.20| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1824.00 | +231.80 | +14.56% |
| R3 | 1729.30 | +137.10 | +8.61% |
| R2 | 1677.00 | +84.80 | +5.33% |
| R1 | 1634.60 | +42.40 | +2.66% |
| PIVOT | 1582.30 | -9.90 | -0.62% |
| CURRENT | 1592.20 | — | — |
| S1 | 1539.90 | -52.30 | -3.28% |
| S2 | 1487.60 | -104.60 | -6.57% |
| S3 | 1445.20 | -147.00 | -9.23% |
| S4 | 1350.50 | -241.70 | -15.18% |
ONESOURCE is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹1535.5–₹1555.9
Trading Above opening range, showing Bullishness
ONESOURCE SPECL PHARMA L financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for ONESOURCE SPECL PHARMA L — consolidated or standalone — with margins, YoY growth and key ratios inline.
ONESOURCE SPECL PHARMA L reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹18,225.24 Cr. and reported EPS of ₹4.47.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,445 | 1,422 ▼ 1.6% |
| Sales Growth YoY %Derived | — | -1.61% |
| Other Income | 17 | 15 ▼ 14.0% |
| Total Income | 1,462 | 1,437 ▼ 1.8% |
| 435 | 445 ▲ 2.2% | |
| Gross ProfitDerived | 1,010 | 977 ▼ 3.3% |
| Gross Margin %Derived | 69.89% | 68.72% |
| 543 | 673 ▲ 23.8% | |
| EBITDA (Operating Profit)Derived | 467 | 304 ▼ 34.8% |
| OPM %Derived | 32.29% | 21.40% |
| 329 | 391 ▲ 18.8% | |
| Profit Before Tax (PBT) | -67 | -92 ▼ 37.1% |
| -50 | -18 ▲ 63.5% | |
| Effective Tax %Derived | 74.23% | 19.75% |
| Profit/Loss from Discontinued Ops | -1 | — ▲ 100.0% |
| Total Profit for Period | -17 | -74 ▼ 327.1% |
| Net Profit (Owner's PAT)Derived | -17 | -74 ▼ 327.1% |
| Net Profit Margin %Derived | -1.20% | -5.19% |
| PAT Growth YoY %Derived | — | -327.08% |
| Earnings Per Share (EPS ₹) | -1.57 | -6.44 ▼ 310.2% |
| Diluted Shares Outstanding (Cr) | 11 | 11 ▲ 0.2% |
| Other Comprehensive Income (Net of Tax) | -3 | 16 ▲ 605.8% |
| Total Expenses (incl. D&A & Interest) | 1,529 | 1,529 ▼ 0.1% |
| Material Cost % of RevenueDerived | 22.72% | 30.72% |
| Employee Cost % of RevenueDerived | 14.90% | 17.04% |
| Other Cost % of RevenueDerived | 22.70% | 30.28% |
| Interest Coverage (x)Derived | 1.16x | 0.21x |
| Period | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|
| Revenue from Operations | 1,445 | 1,422 ▼ 1.6% | |
| Sales Growth YoY %Derived | — | -1.61% | |
| Other Income | 17 | 15 ▼ 14.0% | |
| Total Income | 1,462 | 1,437 ▼ 1.8% | |
435 | 445 ▲ 2.2% | ||
| Gross ProfitDerived | 1,010 | 977 ▼ 3.3% | |
| Gross Margin %Derived | 69.89% | 68.72% | |
543 | 673 ▲ 23.8% | ||
| EBITDA (Operating Profit)Derived | 467 | 304 ▼ 34.8% | |
| OPM %Derived | 32.29% | 21.40% | |
329 | 391 ▲ 18.8% | ||
| Profit Before Tax (PBT) | -67 | -92 ▼ 37.1% | |
-50 | -18 ▲ 63.5% | ||
| Effective Tax %Derived | 74.23% | 19.75% | |
| Profit/Loss from Discontinued Ops | -1 | — ▲ 100.0% | |
| Total Profit for Period | -17 | -74 ▼ 327.1% | |
| Net Profit (Owner's PAT)Derived | -17 | -74 ▼ 327.1% | |
| Net Profit Margin %Derived | -1.20% | -5.19% | |
| PAT Growth YoY %Derived | — | -327.08% | |
| Earnings Per Share (EPS ₹) | -1.57 | -6.44 ▼ 310.2% | |
| Diluted Shares Outstanding (Cr) | 11 | 11 ▲ 0.2% | |
| Other Comprehensive Income (Net of Tax) | -3 | 16 ▲ 605.8% | |
| Total Expenses (incl. D&A & Interest) | 1,529 | 1,529 ▼ 0.1% | |
| Material Cost % of RevenueDerived | 22.72% | 30.72% | |
| Employee Cost % of RevenueDerived | 14.90% | 17.04% | |
| Other Cost % of RevenueDerived | 22.70% | 30.28% | |
| Interest Coverage (x)Derived | 1.16x | 0.21x |
ONESOURCE SPECL PHARMA L segment analysis : revenue and profit mix.
Disclosed business segments at ONESOURCE SPECL PHARMA L with their share of revenue and profit, switchable between consolidated and standalone reporting.
ONESOURCE SPECL PHARMA L discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for ONESOURCE SPECL PHARMA L.
Our AI distills the core fundamental drivers supporting ONESOURCE SPECL PHARMA L, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
ONESOURCE SPECL PHARMA L's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
ONESOURCE SPECL PHARMA L peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — ONESOURCE SPECL PHARMA L is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
ONESOURCE SPECL PHARMA L chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for ONESOURCE SPECL PHARMA L — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
ONESOURCE SPECL PHARMA L delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for ONESOURCE SPECL PHARMA L over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in ONESOURCE SPECL PHARMA L stood at 39.8% of traded volume, against a 20-day average of 49.6%.
ONESOURCE SPECL PHARMA L announcements: results, concalls, ratings, M&A.
Filings ONESOURCE SPECL PHARMA L sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
ONESOURCE SPECL PHARMA L files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 156 documents below.
Updates
Onesource Specialty Pharma Limited has informed the Exchange regarding 'Addendum to the notice of the 19th AGM scheduled to be held on September 23,…
Investor Presentation
Onesource Specialty Pharma Limited has informed the Exchange about Investor Presentation
Copy of Newspaper Publication
Onesource Specialty Pharma Limited has informed the Exchange about Copy of Newspaper Publication confirming dispatch of Notice of the 19th Annual…
Updates
Onesource Specialty Pharma Limited has informed the Exchange regarding 'Intimation of Business Responsibility and Sustainability Report for FY 25-26'.
Shareholders meeting
Onesource Specialty Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 23, 2026
Investor decks & rating reports.
ONESOURCE SPECL PHARMA L dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue ONESOURCE SPECL PHARMA L has declared, sequenced by announce and record date.
ONESOURCE SPECL PHARMA L corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
ONESOURCE SPECL PHARMA L insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in ONESOURCE SPECL PHARMA L as reported to SEBI — buying and selling signals from the people who know the business best.
ONESOURCE SPECL PHARMA L insider activity below tracks 10 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Pronomz Ventures LLP | Insider | 13 Jun 2025 | sell | −51.03 L | ₹1,008.77 Cr. | ₹1,977.00 |
| Sajitha Pillai | Insider | 06 Feb 2025 | sell | −5.0 K | ₹77.39 L | ₹1,547.84 |
| Sajitha Pillai | Insider | 05 Feb 2025 | sell | −7.5 K | ₹1.15 Cr. | ₹1,532.06 |
| Hemalatha Pillai | Insider | 03 Feb 2025 | sell | −18.0 K | ₹2.62 Cr. | ₹1,453.07 |
| Neeraj Sharma | Insider | 03 Feb 2025 | sell | −20.0 K | ₹2.97 Cr. | ₹1,487.15 |
| Vineetha Mohankumar Pillai | Insider | 31 Jan 2025 | sell | −47.5 K | ₹7.44 Cr. | ₹1,565.38 |
| Padmakumar Karunakaran Pillai | Insider | 31 Jan 2025 | sell | −50.0 K | ₹7.79 Cr. | ₹1,558.73 |
| Hemalatha Pillai | Insider | 31 Jan 2025 | sell | −12.0 K | ₹1.9 Cr. | ₹1,579.62 |
| Tenshi Pharmaceuticals Private Limited | Insider | 31 Jan 2025 | sell | −33.01 L | ₹505.62 Cr. | ₹1,531.74 |
| Pronomz Ventures LLP | Insider | 31 Jan 2025 | sell | −5.83 L | ₹90 Cr. | ₹1,545.00 |
About ONESOURCE SPECL PHARMA L: business, sector, key facts.
What ONESOURCE SPECL PHARMA L does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
ONESOURCE SPECL PHARMA L operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: ONESOURCE, BSE: 544292.
ONESOURCE Specialty Pharma Limited is a biopharmaceutical company headquartered in Bengaluru, India, focusing on the research, development, manufacturing, and commercialization of biological drug products. Their primary market is both within India and internationally. The company's core business revolves around providing high-quality biologics in various injectable formats, catering to a broad spectrum of pharmaceutical needs.
A significant aspect of ONESOURCE's operations is its comprehensive contract development and manufacturing organization (CDMO) services. These services span the entire lifecycle of drug development, from the preclinical and clinical phases all the way through to the commercial supply of biologics. This end-to-end approach offers clients a streamlined and integrated solution for bringing their biopharmaceutical products to market.
Beyond its CDMO capabilities, ONESOURCE also boasts a robust manufacturing portfolio. This includes the production of a diverse range of drug delivery devices, such as prefilled syringes, various types of pen injectors, and autoinjectors. In addition to these drug-device combinations, they manufacture sterile injectables, soft gelatin capsules, and a variety of biologics solutions. Their manufacturing expertise extends to diverse biopharmaceutical modalities such as microbial and mammalian cell line biopharmaceuticals, cell and gene therapy products, and RNA-based therapeutics.
ONESOURCE's wide-ranging capabilities and integrated approach position it as a significant player in the global biopharmaceutical landscape. The company's commitment to quality and its broad service offering enable it to support the development and supply of a wide variety of biologics, contributing to advancements in healthcare both domestically and internationally. Its recent name change from Stelis Biopharma Limited to ONESOURCE Specialty Pharma Limited reflects a strategic shift towards highlighting its comprehensive and integrated service offering to clients.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about ONESOURCE SPECL PHARMA L (ONESOURCE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of ONESOURCE SPECL PHARMA L (ONESOURCE)?
The current share price of ONESOURCE SPECL PHARMA L (ONESOURCE) is ₹1,592.20. Today, the stock has gained by ₹50.30 (3.26%), trading in a range of ₹1,530.00 to ₹1,624.70. The stock opened at ₹1,548.10 with a trading volume of 9,19,086 shares.
02Is ONESOURCE SPECL PHARMA L stock a good investment for long-term?
ONESOURCE SPECL PHARMA L can be considered for long-term investment based on several factors. The company has a market capitalization of ₹18,225.24 Cr., P/E ratio of 0, ROE of 0.36%, and ROCE of 1.97%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of ONESOURCE SPECL PHARMA L stock?
The 52-week high price of ONESOURCE SPECL PHARMA L (ONESOURCE) is ₹1,925.00, while the 52-week low is ₹1,057.00. Currently trading at ₹1,592.20, the stock is 50.63% above its 52-week low and 17.29% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy ONESOURCE SPECL PHARMA L stock at the current price?
Whether to buy ONESOURCE SPECL PHARMA L stock at ₹1,592.20 depends on multiple factors. The stock is currently trading with a P/E ratio of 0 and P/B ratio of 3.12. Today's performance shows a gain of 3.26%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of ONESOURCE SPECL PHARMA L and when is the next dividend?
ONESOURCE SPECL PHARMA L offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹1,592.20, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of ONESOURCE SPECL PHARMA L?
ONESOURCE SPECL PHARMA L's key financial metrics include: P/E Ratio: 0, P/B Ratio: 3.12, ROE: 0.36%, ROCE: 1.97%, Dividend Yield: 0%, EPS: ₹4.47, Book Value: ₹508.64, and Debt-to-Equity: 0.21. The company's market cap stands at ₹18,225.24 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is ONESOURCE SPECL PHARMA L stock performing today in the market?
ONESOURCE SPECL PHARMA L stock opened at ₹1,548.10 and is currently trading at ₹1,592.20, showing a gain of ₹50.30 (3.26%). The intraday high is ₹1,624.70 and low is ₹1,530.00. The trading volume stands at 9,19,086 shares, indicating moderate market participation today.
08What is the P/E ratio of ONESOURCE SPECL PHARMA L and what does it indicate?
ONESOURCE SPECL PHARMA L has a Price-to-Earnings (P/E) ratio of 0, which means investors are willing to pay 0.00 for every ₹1 of earnings. With an EPS of ₹4.47, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about ONESOURCE SPECL PHARMA L (ONESOURCE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.